Piper Sandler lowered the firm’s price target on CytomX Therapeutics (CTMX) to $3.25 from $3.50 and keeps an Overweight rating on the shares following Q3 results. Cash of $118M provides runway to end of 2025, so a bit tight, but excludes any future potential milestones, Piper told investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks